Europe Coronary Stent Market

Europe Coronary Stent Market Size (2022 to 2027)

The size of the European coronary stent market was worth USD 2.57 billion in 2022 and is estimated to be growing at a CAGR of 7.2% to reach USD 3.64 billion by 2027.

A stent is a medical device implanted in the body to treat cardiac abnormalities such as blocked blood vessels. Besides, stents are embedded in the esophagus to allow the passage of food and beverages in patients with oesophageal cancer. They are also inserted in the ureter to prevent obstruction of urine flow from the kidney. Stents are generally made of metals, polymers, and natural bioabsorbable materials.

The increase in cardiovascular disorders is a prime reason for the increasing demand for coronary stents. One of the significant causes behind increasing cardiovascular conditions is the increased adoption of an unhealthy lifestyle. Changing lifestyles, such as smoking, physical inactivity, and unhealthy diet, hamper the heart's health. An aging population is another factor that is driving the growth of these products at a significant rate.

The growing age of people, particularly in older people who are more prone to heart-related disorders who need to undergo surgeries related to stents, is a significant factor boosting the coronary stents market growth in the European region. The key players who are attentive are coming up with new devices in the medical field of the coronary stents market is to accelerate the growth during the forecast period. Increasing demand for these stents to perform surgical procedures when the patient's arteries or valves get blocked is some factors surging the coronary stents market. Unhealthy lifestyles may also lead to heart-related problems that drive the stent market growth over the review period.

Stringent regulations for product approval may cause a hindrance to the growth of the market. High costs associated with the devices, lack of awareness among the patients related to stents in cardiology, and the shortage of expert professionals during the treatment of stents, availability of alternative treatment procedures for coronary stent devices are majorly impeding the market growth during the foreseen period. Side-affects that arise post-surgery of stents may also limit the market growth. Also, product recalls, and failure of the usage of the devices is obstructing the development of the coronary stents market.

This research report on the European Coronary stents market has been segmented & sub-segmented into the following categories:

By Type: 

• Bare Metal Stents
• Drug-Eluting Stents
• Bioabsorbable Stents

By Mode of Delivery: 

• Balloon Expandable Stents 
• Self-Expanding Stents

By Material: 

• Metallic stents
  • Cobalt chromium
  • Platinum chromium
  • Nickel-titanium
  • Stainless steel
• Other Stents

By End-User: 

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Based on geography, Europe holds a considerable share in the global market and is expected to grow steadily. Factors like advanced technologies with the latest versions of the stents and increasing cardiovascular diseases propel the market.

The German coronary stent market is expected to lead the European coronary stent market during the forecast period due to increasing cardiac disorder rates among the people, which surge the market growth over the period. Drug-eluting stents and Bioresorbable vascular segment is expected to drive the country of this region.

UK, France, Spain, and Italy are also expected to contribute well to the European market due to the increasing occurrence rate of heart attacks and chest pains, which accelerate the coronary stents market growth over the forecast period.

KEY MARKET PLAYERS:

A few of the promising companies operating in the Europe Coronary stent market profiled in this report are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, TERUMO CORPORATION, STENTYS SA, MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., Vascular Concepts, and Translumina GmbH.